Pancreatic cancer took Alex Trebek, Michael Landon, Ruth Bader Ginsburg, Luciano Pavarotti, Steve Jobs, Patrick Swayze, and my dear friend Amy. Glioblastoma (GBM) took Senators John McCain and Ted Kennedy, Neil Peart (of the band Rush), Canadian singer Gord Downie, Irene Ryan (Granny on The Beverly Hillbillies), award-winning cellist Antonio Meneses, and Katie DiSimone, whose selfless work and free sharing helped thousands with diabetes.
RadioMedix, a company in Humble Texas, and Vect-Horus, a biotechnology company in Marseille, France, are jointly working on a new approach to these two very difficult cancers: Glioblastoma Multiforme (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC). Leaders from both of these companies are hoping that this new approach will prove to be a significant treatment option. Previous research studies showed strong tumor uptake, supporting its potential as a theranostic tool – one that a both help to diagnose and treat hard-to-treat cancers.
The very first brave patient has been dosed in an exploratory investigational new drug study of 203Pb-RMX-VH-PIB. This is a “radiopharmaceutical” designed to target the Low-Density Lipoprotein Receptor (LDLR) in aggressive cancers. The agent, which can cross the blood-brain barrier, is being evaluated for safety, dosimetry (measuring the absorbed dose of radiation), and tumor-targeting, with the goal of serving as a companion diagnostic for future Targeted Alpha Therapy (TAT).
Such research is indeed, Patient Worthy. We await further updates.
